前沿速览018期| CAR-T治B淋 前沿览新知
01
现货型CAR-T治疗复发或难治性B细胞恶性肿瘤：2023ASH年会进展综述
Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting
第一作者：Kang Y
J Hematol Oncol (IF=28.5). 2024 May 6;17(1):29.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075181/
02
综合桥接放疗在CAR-T治疗非霍奇金淋巴瘤中的作用
Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma
第一作者：Saifi O
JAMA Oncol (IF=28.4). 2024 May 9:e241113.
全文网址：https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.1113
03
靶向激活小胶质细胞中的TGFβ激活激酶-1可减轻CAR-T治疗相关的ICANS
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
第一作者：Vinnakota JM
Nat Cancer (IF=22.7). 2024 May 13.
全文网址：https://www.nature.com/articles/s43018-024-00764-7
04
CAR-T与双特异性抗体治疗≥3线大B细胞淋巴瘤的比较：一项荟萃分析
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis
第一作者：Kim J
Blood (IF=20.3). 2024 May 2:blood.2023023419.
全文网址：https://ashpublications.org/blood/article/doi/10.1182/blood.2023023419/515999/Comparison-of-CAR-T-cell-vs-bispecific-antibody-as
05
CAR-T细胞在CAR介导的效应功能方面优于CAR-NK细胞
CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison
第一作者：Egli L
Exp Hematol Oncol (IF=11.4). 2024 May 14;13(1):51.
全文网址：https://ehoonline.biomedcentral.com/articles/10.1186/s40164-024-00522-6
06
靶向CD20 CAR-T细胞治疗淋巴瘤获长期缓解
Long-term Remissions Following CD20-directed Chimeric Antigen Receptor Adoptive T cell Therapy
第一作者：Mo G
Blood Cancer Discov (IF=11.2). 2024 May 15.
全文网址：https://aacrjournals.org/bloodcancerdiscov/article-abstract/doi/10.1158/2643-3230.BCD-23-0263/745329/Long-term-Remissions-Following-CD20-directed?redirectedFrom=fulltext
07
CD19免疫PET用于非侵入性可视化检测B细胞淋巴瘤患者CD19的表达
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
第一作者：Sonanini D
Biomark Res (IF=11.1). 2024 May 12;12(1):50.
全文网址：https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-024-00595-9
08
隐形转基因使CAR-T细胞能够逃避宿主免疫反应
Stealth transgenes enable CAR-T cells to evade host immune responses
第一作者：Grauwet K
J Immunother Cancer (IF=10.9). 2024 May 9;12(5):e008417.
全文网址：https://jitc.bmj.com/content/12/5/e008417.long
09
CAR-T治疗继发性中枢神经系统受累的套细胞淋巴瘤：多中心经验
CAR T-cell Therapy in Mantle Cell Lymphoma with Secondary CNS Involvement - a multicenter experience
第一作者：Ahmed G
Blood Adv (IF=7.6). 2024 May 3:bloodadvances.2023012255.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023012255/516005/CAR-T-cell-Therapy-in-Mantle-Cell-Lymphoma-with
10
新型抗CD19 CAR-T疗法治疗复发性滤泡性淋巴瘤，应答快速伴假性进展和巨细胞病毒感染：病例报告
Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report
第一作者：Zhong N
Int Immunopharmacol (IF=5.6). 2024 May 3;134:112174.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S1567-5769(24)00692-1
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.5-16 valid until 2026.5
供稿与审核：临床开发与医学部